NO20080497L - Pyrrolopyridinderivater og anvendelse av disse som PPAR-reseptormodulatorer - Google Patents

Pyrrolopyridinderivater og anvendelse av disse som PPAR-reseptormodulatorer

Info

Publication number
NO20080497L
NO20080497L NO20080497A NO20080497A NO20080497L NO 20080497 L NO20080497 L NO 20080497L NO 20080497 A NO20080497 A NO 20080497A NO 20080497 A NO20080497 A NO 20080497A NO 20080497 L NO20080497 L NO 20080497L
Authority
NO
Norway
Prior art keywords
ppar
alkyl
pyrrolopyridine derivatives
salts
new
Prior art date
Application number
NO20080497A
Other languages
English (en)
Other versions
NO340681B1 (no
Inventor
Pierre Dodey
Christiane Legendre
Martine Barth
Olivia Poupardin-Olivier
Boubia Benaissa
Jean Binet
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Publication of NO20080497L publication Critical patent/NO20080497L/no
Publication of NO340681B1 publication Critical patent/NO340681B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Oppfinnelsen angår pyrrolopyridinbaserte forbindelser med generell formel (I): (I) slik som definert i kravene, og til de farmasøytisk akseptable addisjonssaltene derav. Oppfinnelsen angår også fremgangsmåten for fremstilling av nevnte forbindelser, til farmasøytiske preparater som inneholder dem og til anvendelse av dem som farmakologisk aktive substanser, spesielt ved behandling av hypertriglyceridemi, hyperlipidemi, hyperkolesterolemi, diabetes, endotel funksjonsforstyrrelse, kardiovaskulære sykdommer, inflammatoriske sykdommer og neurodegenerative sykdommer.
NO20080497A 2005-09-01 2008-01-28 Pyrrolopyridinderivater, framgangsmåte for fremstilling, farmasøytisk praparater omfattende slike, slike forbindelser som farmakologisk aktive substanser samt anvendelse av slike forbindelser og preparater for behandling av sykdom NO340681B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71345905P 2005-09-01 2005-09-01
FR0510482A FR2890072A1 (fr) 2005-09-01 2005-10-14 Nouveaux composesde pyrrolopyridine
PCT/FR2006/050827 WO2007026104A1 (fr) 2005-09-01 2006-08-31 Derives de pyrrolopyridine et leurs utilisations comme modulateurs des recepteurs ppar

Publications (2)

Publication Number Publication Date
NO20080497L true NO20080497L (no) 2008-02-29
NO340681B1 NO340681B1 (no) 2017-05-29

Family

ID=37735036

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080497A NO340681B1 (no) 2005-09-01 2008-01-28 Pyrrolopyridinderivater, framgangsmåte for fremstilling, farmasøytisk praparater omfattende slike, slike forbindelser som farmakologisk aktive substanser samt anvendelse av slike forbindelser og preparater for behandling av sykdom

Country Status (27)

Country Link
US (2) US7557122B2 (no)
EP (1) EP1919474B1 (no)
JP (1) JP5232000B2 (no)
KR (1) KR101289589B1 (no)
CN (1) CN101242833B (no)
AT (1) ATE438396T1 (no)
AU (1) AU2006286348B2 (no)
BR (1) BRPI0615335A2 (no)
CA (1) CA2620662C (no)
DE (1) DE602006008320D1 (no)
DK (1) DK1919474T3 (no)
EA (1) EA014185B1 (no)
ES (1) ES2331336T3 (no)
FR (1) FR2890072A1 (no)
HK (1) HK1116698A1 (no)
HR (1) HRP20090512T1 (no)
IL (1) IL189189A (no)
MX (1) MX2008003038A (no)
MY (1) MY142983A (no)
NO (1) NO340681B1 (no)
PL (1) PL1919474T3 (no)
PT (1) PT1919474E (no)
SI (1) SI1919474T1 (no)
TN (1) TNSN08091A1 (no)
UA (1) UA92026C2 (no)
WO (1) WO2007026104A1 (no)
ZA (1) ZA200801885B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007145434A (ru) * 2005-05-10 2009-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов ионных каналов
FR2890071B1 (fr) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
JP2010528991A (ja) * 2007-05-21 2010-08-26 エスジーエックス ファーマシューティカルズ、インコーポレイテッド 複素環式キナーゼ調節因子
FR2955110A1 (fr) * 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
FR2955108B1 (fr) 2010-01-08 2012-03-16 Fournier Lab Sa Utilisation de derives de pyrrolopyridine comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
WO2013122897A1 (en) * 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CN103630519A (zh) * 2013-12-03 2014-03-12 华东理工大学 应用pH敏感的比率荧光蛋白检测酶-前药反应的方法
CN108164528B (zh) * 2018-03-31 2019-03-22 杭州巴洛特生物科技有限公司 一种酰胺类衍生物及其在高血压、高血脂和动脉粥样硬化中的应用
CN108456207B (zh) * 2018-03-31 2020-11-20 浙江药苑生物科技有限公司 一种酰胺类衍生物及其在心脑血管方面的应用
CN108218865B (zh) * 2018-03-31 2020-06-26 济南市儿童医院 一种酰胺类衍生物及其在心脑血管方面的应用
CN108383838B (zh) * 2018-03-31 2020-08-28 浙江药苑生物科技有限公司 一种酰胺类衍生物及其在高血压、高血脂和动脉粥样硬化中的应用
CN111793066B (zh) * 2020-07-17 2022-04-08 瀚海新拓(杭州)生物医药有限公司 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
EA002817B1 (ru) 1996-12-13 2002-10-31 Авентис Фармасьютикалз Продактс Инк. Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)азагетероциклиламида
WO2001060807A1 (en) 2000-02-18 2001-08-23 Merck & Co. Inc. Aryloxyacetic acids for diabetes and lipid disorders
WO2002071827A2 (en) 2001-03-14 2002-09-19 Eli Lilly And Company Retinoid x receptor modulators
MXPA04004711A (es) * 2001-11-19 2005-08-16 Neurogen Corp Amidas del acido 1h-pirrolo(3,2-b(piridin-3-carboxilico.
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
DE10300099A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Indol-Phenylsulfonamid-Derivate
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
KR20130023381A (ko) * 2003-07-17 2013-03-07 플렉시콘, 인코퍼레이티드 Ｐｐａｒ 활성 화합물
DE10335449A1 (de) 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
DE10335450A1 (de) 2003-08-02 2005-02-17 Bayer Ag Indolin-Sulfanilsäureamide
EP1689389A4 (en) 2003-12-04 2009-06-17 Nat Health Research Institutes Indole compounds

Also Published As

Publication number Publication date
HK1116698A1 (en) 2009-01-02
US7557122B2 (en) 2009-07-07
BRPI0615335A2 (pt) 2012-12-11
ATE438396T1 (de) 2009-08-15
ES2331336T3 (es) 2009-12-29
UA92026C2 (uk) 2010-09-27
FR2890072A1 (fr) 2007-03-02
DE602006008320D1 (de) 2009-09-17
DK1919474T3 (da) 2009-11-09
JP5232000B2 (ja) 2013-07-10
AU2006286348A1 (en) 2007-03-08
AU2006286348B2 (en) 2012-04-26
EA200800352A1 (ru) 2008-06-30
EP1919474A1 (fr) 2008-05-14
JP2009507007A (ja) 2009-02-19
CN101242833A (zh) 2008-08-13
US7728002B2 (en) 2010-06-01
NO340681B1 (no) 2017-05-29
ZA200801885B (en) 2009-08-26
CA2620662C (fr) 2015-10-06
WO2007026104A1 (fr) 2007-03-08
IL189189A0 (en) 2008-06-05
IL189189A (en) 2013-10-31
CA2620662A1 (fr) 2007-03-08
CN101242833B (zh) 2012-06-27
PT1919474E (pt) 2009-10-28
KR20080039908A (ko) 2008-05-07
SI1919474T1 (sl) 2009-12-31
EA014185B1 (ru) 2010-10-29
TNSN08091A1 (fr) 2009-07-14
MX2008003038A (es) 2008-03-24
EP1919474B1 (fr) 2009-08-05
MY142983A (en) 2011-02-14
US20090239856A1 (en) 2009-09-24
PL1919474T3 (pl) 2010-03-31
HRP20090512T1 (hr) 2009-12-31
KR101289589B1 (ko) 2013-07-24
US20080200495A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
NO20080497L (no) Pyrrolopyridinderivater og anvendelse av disse som PPAR-reseptormodulatorer
DK1919869T3 (da) Indolderivater som PPAR-aktivatorer
MY154836A (en) Activating agent for peroxisome prolifrator activated receptor ?
DK1349843T3 (da) Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
NO20035086D0 (no) Karboksylsyresubstituerte oxazolderivater for anvendelse som PPAR-alfa og gamma-aktivatorer i behandling av diabetes
DE60018064D1 (de) Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
NO20062030L (no) Derivater av N-heterocyklylmetylbenzamider, fremgangsmate for fremstilling derav og anvendelse av forbindelsene t terapeutiske midler.
NO20054408D0 (no) 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
NO20053561L (no) Mettede kinoksalinderivater og deres anvendelse som metabotrofe og glutamatreseptorligander
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
HUP0102277A2 (hu) 3-Helyzetben heterociklusos csoporttal szubsztituált benzoesavszármazékot tartalmazó herbicid készítmény előállítása és alkalmazása
NO20030729L (no) Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister
DK1828125T3 (da) Arylpiperazinderivater og deres anvendelse som selektive ligander for dopaminets D3 receptor
AU2003207808A1 (en) Peroxisome proliferator activated receptor modulators
NO20074738L (no) Aktivator for peroksisom-proliferator som aktiverer reseptor delta
ES2165410T3 (es) Nuevas 5-(ariloxi-metil)-oxazolinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
WO2008146917A1 (ja) リンコマイシン誘導体及びこれを有効成分とする抗菌剤
CA2490152A1 (en) Oxazole derivatives and their use as insulin sensitizers
NO20075505L (no) 7-fluor-1,3-dihydro-indol-2-on oksazolidinoner som antibakterielle forbindelser
DK1778655T3 (da) 2-{-3-'2-(phenyl)-oxazol-4-ylmethoxy!-cyclohexylmethoxy}-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes
AR022352A1 (es) COMPUESTOS HERBICIDAS DE ÁCIDO PROPIoNICO ALCOXICARBONIL ANILIDA ALTAMENTE SELECTIVOS, SUS COMPOSICIONES HERBICIDAS, SUS MÉTODOS DE PREPARACIoN Y COMPUESTO INTERMEDIARIO Y MÉTODO PARA CONTROLAR EL PASTO.
TH71078A (th) อนุพันธ์ซับสทิทิวเทด 3-(เบนโซอิลยูริไอโด)ไธโอฟีน, กรรมวิธีสำหรับการเตรียมอนุพันธ์เหล่านี้ และการใช้อนุพันธ์เหล่านี้

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: INVENTIVA, FR

MM1K Lapsed by not paying the annual fees